Versantis AG received USFDA approval for VS-01 for the Treatment of Urea Cycle Disorders

▴ Versantis AG received USFDA approval for VS-01 for the Treatment of Urea Cycle Disorders
Versantis receives US FDA rare pediatric disease designation for VS-01 for the treatment of urea cycle disorders

Versantis AG, a clinical-stage company developing novel therapies for orphan liver diseases, announced that the U.S. Food and Drug Administration (FDA) has granted a rare pediatric disease designation (RPDD) to its lead product candidate VS-01, an ammonia clearance enhancer, for the treatment of Urea Cycle Disorders (UCD). UCD is a rare and life-threatening condition caused by an inherited inborn error of metabolism. Current treatment options are associated with poor outcomes.

“The rare pediatric disease designation highlights the potential of using VS-01 to treat the serious and life-threatening manifestations of UCD,” said Meriam Kabbaj, Chief Operations Officer and Co-founder of Versantis. “It is valuable recognition that will help Versantis to ramp up its pediatric program by fostering collaborations with key opinion leader and patients’ associations.”

The FDA grants rare pediatric disease designation for serious or life-threatening diseases primarily affecting children from birth to 18 years and affecting fewer than 200,000 people in the USA. Upon approval of a new drug application, the RPDD renders sponsor companies eligible for a priority review voucher, which can be redeemed to obtain accelerated FDA review of a drug candidate, is any indication, potentially gaining early market access. This voucher may be sold or transferred to another sponsor.

Versantis recently completed a $16M Series B financing round and is currently raising new funds to fuel VS-01 clinical development in rare indications, including UCD.

“This recognition acknowledges the unmet medical needs of children with UCD. Importantly, with this designation, we may qualify to receive a priority review voucher from FDA, at the time of marketing approval of VS-01. It provides significant value to our current effort to develop effective treatments for this devastating rare disease,” said Vincent Forster, Versantis’ Co-founder and CEO.

VS-01 is an innovative liposomal-based detoxification therapy that acts as a clearance enhancer for a large spectrum of toxic metabolites accumulated during liver and kidney failures. More specifically, VS-01 clears ammonia from the body, which is the main neurotoxic metabolite and can lead to brain edema. With its rapid onset, VS-01 could be the first-line medication of choice for acute hyperammonemia in an emergency setting. VS-01 is currently being evaluated in clinical trials in decompensated cirrhotic patients.

Urea cycle disorder is an orphan condition that predominantly affects children where patients present with hyperammonemia either shortly after birth (about 50%) or, later at any age, leading to death or to severe neurological handicap. The clinical course in newborns is characterized by an initial hyperammonemic crisis shortly after birth progressively leading to somnolence, lethargy, coma and death. In hyperammonemic crises, dialysis is used to drastically lower ammonia levels, however, it can only be performed in highly specialized tertiary centres and is often initiated too late. Up to 90% of newborns do not survive the initial event of acute hyperammonemia or suffer from severe neurological sequelae. Curative orthotopic liver transplantation can be performed in children from about 10 kg body weight. VS-01 is principally intended as bridging therapy until the children are old enough and have reached the appropriate body weight and/or until they can access a tertiary centre.

Tags : #VersantisAG #LatestUSFDAApproval19thOct #LatestPharmaNews19thOct #TreatmentofUreaCycleDisorders #MeriamKabbaj #VincentForster #OrphanLiverDiseases #LatestNewsonVersantisAG19thOct

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Eyes on the Future: Dr. Agarwal's Group Channels Rs 100 Crore for Cutting-edge Eye Hospitals Across KeralaDecember 06, 2023
Organ Transplant Scandal: Apollo Hospital Faces Government InquiryDecember 06, 2023
Breaking Barriers in Cancer Treatment: Max Healthcare's CAR-T Therapy PartnershipDecember 06, 2023
Exploring the Link Between Covid-19 Vaccination and Sudden Cardiac Arrests: ICMR StudyNovember 22, 2023
Powering the Future: China's Biodegradable Wireless System for Bioelectronic InnovationNovember 22, 2023
IMS BHU Pioneers Advanced Cardiac Care: Unveiling Cutting-Edge Technologies for Precise DiagnosisNovember 18, 2023
Inito's $6 Million Boost: Transforming Women's Health with AI-Backed Fertility MonitoringNovember 18, 2023
Madras High Court Advocates for Equality: PG Medical Students to Receive Incentive Marks for COVID-19 DutyNovember 18, 2023
Next-Gen Healthcare: CarePods and AI Redefine the Patient ExperienceNovember 17, 2023
Air Quality Crisis: Alarming Rise in Premature Births Linked to Air Quality in Begusarai, BiharNovember 17, 2023
Limerick Contest-2023: A Celebration of Wit and PoetryNovember 17, 2023
IIIT-Hyderabad among top 100 institutions for 5G Use Case LabNovember 17, 2023
Powerful, motivating and inspiring talks marked TEDx Hyderabad Women 2023 which was held with the theme "Two Steps ForwardNovember 17, 2023
Speaking the Diagnosis: How AI in Voice Analysis Is Revolutionizing Diabetes DetectionNovember 17, 2023
FDA Approves Zepbound: A New Medication for Weight Loss by Eli LillyNovember 17, 2023
CoverSelf Raises $8.2 Million in Seed Funding to Revolutionize Healthcare Claims with Innovative Fintech PlatformNovember 16, 2023
From Miracle to Medic: The Extraordinary Journey of India's First Paediatric Liver Transplant RecipientNovember 16, 2023
Combatting Chikungunya: Valneva's Chikungunya Vaccine Cleared by USFDA, Eyes India LaunchNovember 16, 2023
Global Corporate Summit 2023 with the theme Unlocking Opportunities in a Dynamic World heldNovember 16, 2023
2nd IHub-Data Mobility Summit heldNovember 16, 2023